Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Date publication

mai 2026

Journal

Neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Gavoille A, Kerbrat A, Edan G, Le Page E, Rollot F, Casey R, Mathey G, Stankoff B, Ciron J, De Seze J, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, David T, Magy L, Camdessanche JP, Moulin S, Doghri I, Sarov M, Dos Santos A, Pottier C, Manchon E, Aboab J, Tchikviladze M, Dahan C, Durozard P, Scherer-Gagou C, Leclancher A, Laplaud DA, Vukusic S, Michel L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42085644

Résumé

The therapeutic strategy for late-onset multiple sclerosis (LOMS) with a relapsing-remitting onset remains unclear, potentially leading to underexposure to disease-modifying therapies (DMTs) compared with adult-onset multiple sclerosis (AOMS). We investigated the differences in DMT use between LOMS and AOMS within the French MS registry at comparable levels of disease severity.

Mots clés

Humans, Female, Adult, Male, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Retrospective Studies, Age of Onset, Registries, Middle Aged, Immunologic Factors, therapeutic use, France, Cohort Studies, Nitriles, therapeutic use, Crotonates, therapeutic use, Natalizumab, therapeutic use, Toluidines, therapeutic use, Hydroxybutyrates

Référence

Neurology. 2026 05 26;106(10):e214943